

## SARS-CoV-2 RBD antibody 3G6

<b>Cat. No.</b>	Ab-P0021						
<b>Product name</b>	SARS-CoV-2 RBD antibody 3G6						
<b>Size</b>	100 µg						
<b>Host Species</b>	Mouse						
<b>Specificity</b>	○ : work, — : not work						
	<table border="1"> <thead> <tr> <th></th> <th>ELISA</th> </tr> </thead> <tbody> <tr> <td>SARS-CoV-1 S1-His</td> <td>○</td> </tr> <tr> <td>SARS-CoV-2 RBD-mFc</td> <td>○</td> </tr> </tbody> </table>		ELISA	SARS-CoV-1 S1-His	○	SARS-CoV-2 RBD-mFc	○
	ELISA						
SARS-CoV-1 S1-His	○						
SARS-CoV-2 RBD-mFc	○						

<b>Form</b>	Liquid
<b>Storage</b>	Store at -20°C. Avoid multiple freeze-thaw cycles.
<b>purity</b>	>90% by SDS-PAGE
<b>Concentration</b>	1mg/ml
<b>Storage buffer</b>	PBS (pH7.4)
<b>Clonality</b>	Monoclonal
<b>Clone number</b>	3G6
<b>Isotype</b>	IgG

<b>Recommended Dilutions</b>	ELISA	1/5,000 – 1/10,000
------------------------------	-------	--------------------

**Backgrounds**

In previous studies, a number of potent monoclonal antibodies against SARS coronavirus (SARS-CoV) have been identified. These antibodies target more specifically the 193 amino acid length (N318-V510) receptor binding domain (RBD) within the S protein is the critical target for neutralizing antibodies. Some of the antibodies recognize different epitopes on RBD, for example the SARS-CoV neutralizing antibodies CR3014 and CR3022 bound noncompetitively to the SARS-CoV RBD and neutralized the virus in a synergistic fashion.

Note : For research use only. Not for use in diagnostic procedures.